Baxter amps up cancer drug contract manufacturing; Aesica teams up with Britest;

> Boehringer Ingelheim has tapped Hungary's ChemAxon and its R&D software to help usher compounds from discovery to the clinic. News

> Takeda plans to lend a helping hand to CMO Nihon Pharmaceuticals as the company grapples with ire from Japanese regulators. Story

> Aesica has partnered with Britest to expand its API-production know-how. Article

> Jamaican CMO Benjamin Manufacturing is getting an earful from the FDA over sterility and quality control. More

> Baxter ($BAX) is responding to the boom in targeted cancer drugs by beefing up its CMO unit's cytotoxic manufacturing capabilities. Report

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.